BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Large Decrease in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,650,000 shares, a decline of 30.7% from the December 15th total of 2,380,000 shares. Approximately 4.2% of the company’s shares are sold short. Based on an average trading volume of 1,540,000 shares, the short-interest ratio is presently 1.1 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

BriaCell Therapeutics Stock Performance

BCTX traded down $0.01 during midday trading on Thursday, reaching $0.39. 400,253 shares of the company were exchanged, compared to its average volume of 1,180,545. The stock has a market capitalization of $17.02 million, a P/E ratio of -0.43 and a beta of 1.55. BriaCell Therapeutics has a one year low of $0.37 and a one year high of $4.61. The stock’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.75.

BriaCell Therapeutics’s stock is scheduled to reverse split before the market opens on Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, January 28th.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its earnings results on Monday, December 16th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). On average, research analysts anticipate that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.